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Background: Frailty in older patients might influence treatment decisions. Frailty can be determined using a
Comprehensive Geriatric Assessment (CGA), but this is time-consuming and expensive. Therefore we assessed the
diagnostic value of four shorter screening instruments.
Methods: We tested the abbreviated CGA (aCGA), the Vulnerable Elders Survey-13 (VES-13), the Groningen Frailty
Indicator (GFI) and the Geriatric 8 (G8). A full CGA including functional status, cognitive status, depression, nutrition
and comorbidity was used as reference. A minimum of 85% for both sensitivity and specificity was predefined as
acceptable. Data were collected through personal interviews by trained interviewers. We assessed people aged ≥
70 years: 108 patients with recently diagnosed cancer recruited in hospitals and 290 without cancer recruited by
general practitioners in the Netherlands and Belgium.
Frailty was defined as having impairment in at least two domains of the full CGA. We used original cut-offs for
the screening instruments and calculated sensitivity, specificity, positive and negative diagnostic values and the
percentage classified as frail.
Results: Sensitivity of aCGA was 79% and 87% for patients with and without cancer; specificity was 59% and 64%.
Sensitivity of VES-13 was 67% and 82% for patients with and without cancer; specificity was 70% and 79%.
Sensitivity for GFI was 76% (in both groups) and specificity 73% (in both groups). Sensitivity for G8 was 87% and
75% for patients with and without cancer; specificity was 68% (in both groups).
Conclusions: No screening instrument was acceptable according to our predefined minimum of 85% for both
sensitivity and specificity. The diagnostic value of the investigated instruments is rather poor and one could wonder
about their additional value to clinical judgment.
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An increase in the number of older people is leading to an
increase in the number of patients diagnosed with cancer
[1]. Older people are a very heterogeneous group with
respect to comorbidity and social and psychosocial func-
tioning [2]. This heterogeneity may complicate treatment
decisions [3,4]. Therefore, treatment of older patients* Correspondence: h.smets@alumni.maastrichtuniversity.nl
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reproduction in any medium, provided the ordemands a specific approach and the presence of frailty
should be taken into account.
Frailty is an ambiguous concept. Fried and colleagues
associated frailty with dependency, institutionalization
and mortality [5,6], but it is also associated with physio-
logical age [2]. From another perspective, frailty is
considered to be a multidimensional concept that is
influenced by biological and physiological factors but
also by personal characteristics and environment [7]. In
addition, frailty is generally considered to be a poten-
tially reversible state, which makes its diagnosis import-
ant [8,9].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Assessment (CGA) [10]. The International Society for
Geriatric Oncology (SIOG) recommends performing a
CGA for all patients diagnosed with cancer aged ≥ 70 years
[11]. However, a CGA is time-consuming and therefore
expensive. An alternative could be the use of validated
shorter screening instruments that indicate whether fur-
ther assessment of geriatric problems using a full CGA
might be relevant [12].
In the present study, four screening instruments for
frailty were compared with a full CGA: the abbreviated
CGA (aCGA) [13], the Vulnerable Elders Survey-13 (VES-
13) [14], the Groningen Frailty Indicator (GFI) [15] and
the Geriatric 8 (G8) [16,17]. These instruments were se-
lected because they are often used in daily care to assess
frailty. Although the validity of the selected screening in-
struments has been studied previously, evidence about
psychometric quality is still limited. A recent study by
Hamaker and colleagues [18] compared eight screening
instruments to a full CGA and found limited discrimina-
tive power with a wide range in sensitivity (25–92%) and
specificity (39–100%). Other recent studies concluded that
screening tools had too little predictive power [19,20] to
identify frailty. In some studies [21], only older patients
with cancer were included to investigate shorter screen-
ing instruments. In other studies [22], only older people
without cancer were included. Identification of frailty is
important for both groups, however, the diagnostic
value of screening instruments might be different in
older cancer patients as many frailty-related symptoms
such as fatigue and nutrition are influenced by (treat-
ments of ) cancer.
We aimed to identify screening instruments that best
assess the risk of frailty in people aged ≥ 70 years with
and without cancer. Since there is still no generally ac-
cepted standard of frailty [18], we decided that having at
least two out of five positive scores on the domains that
are part of the full CGA (i.e., functional status, cogni-
tion, depression, nutritional status and medication use)
was an indication of frailty.
Methods
This study was part of the KLIMOP study [23], which is a
large prospective cohort study conducted at the univer-
sities of Leuven and Hasselt in Belgium and Maastricht in
The Netherlands. It is performed in collaboration with the
Limburg Cancer collaboration foundation (LIKAS), 7 hos-
pitals, 13 general practices in the Netherlands and 31 in
Belgium. The target population of the KLIMOP study
consists of older cancer patients aged ≥ 70 years, older
patients aged ≥ 70 years without a previous diagnosis of
cancer and cancer patients between 50–69 years. For each
group a sample size of 360 participants per country was
proposed, enabling within-country analyses.The aim of the KLIMOP study is to assess the impact
of cancer, aging and their interaction on the well-being
of older cancer patients [23].
Participants
For this study two groups were defined. One group con-
sisted of people aged ≥ 70 years who were recently given
a primary diagnosis of breast, prostate, lung or gastro-
intestinal cancer. This group was recruited at the oncol-
ogy wards of five Belgian and two Dutch hospitals. The
other group consisted of people aged ≥ 70 years without
cancer. This group was recruited through general prac-
tices in Belgium and The Netherlands. Both groups were
recruited between June 2010 and December 2012. Exclu-
sion criteria were the inability to speak Dutch, a formal
diagnosis of dementia, a previous diagnosis of invasive
cancer (except non-melanoma of the skin), being too ill to
participate or a life expectancy shorter than six months
(based on the judgment of the attending doctor) [23]. We
collected data from 509 participants.
Data collection
All participants were assessed by trained interviewers. Par-
ticipants were screened for frailty by means of the aCGA,
VES-13, GFI, G8 and a full CGA. The questions from the
different screening instruments were asked in a personal
interview and the same questions were not asked twice.
The full CGA consists of five domains: functional status,
cognition, depression, nutritional status and medication
use. Functional status was measured by Activities of Daily
Living (ADL) using the Barthel Index [24] and by Instru-
mental ADL using the Lawton IADL-scale [25]. Cognitive
status was assessed by the Mini Mental State Examination
(MMSE) [26]. Depressive symptoms were measured using
the Geriatric Depression Scale (GDS-15) [27]. Nutrition
was assessed by food intake (QOL) [28] and weight loss
(GFI) [15]. Medication use, as reported by the partici-
pants, was included as an indication for morbidity.
Instruments and cut-off values
The cut-off values of the four selected screening instru-
ments were derived from previous studies (Table 1). The
aCGA [13] consists of 15 questions covering three domains:
functional status (seven questions on ADL and IADL), cog-
nitive status (four questions from the MMSE) and depres-
sion (four questions from the GDS-15). A cut-off value was
identified for each domain, indicating whether a more elab-
orate assessment was needed for that domain: ≥ 1 for ADL
and IADL; ≤ 6 for the MMSE; and ≥ 2 for the GDS-4 [21].
A need for further assessment of frailty was indicated if one
of the aCGA domains scored positive.
The VES-13 includes questions about age, self-rated
health-status, physical fitness and need for assistance with
activities. It consists of 13 questions with a maximum
Table 1 Cut-off values for the screening Instruments aCGA, VES-13, GFI, G8, and for the full CGA
DOMAINS aCGA VES- 13 GFI G8 Full CGA
Cut-off maximum Cut-off maximum Cut-off maximum Cut-off maximum Cut-off maximum
Age 3 2
Functional status ≥ 1 7 7 5 4 ≥ 2 19
Cognitive status ≤ 6 8 1 2* ≤ 23 30
Depression ≥ 2 4 5 2* ≥ 8 15
Nutrition 1 8
- Food intake < 2 2
- Weight loss < 3 3
Comorbidity
- Medication use 3 1 >3
INDICATION FOR FRAILTY Positive score
on ≥1 domain
None ≥ 3 10 ≥ 4 15 ≤ 14 17 Positive score
on ≥ 2 domains
None
*Cut-off maximum of 2 for cognitive status or depression.
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3 as an indication of frailty [14].
The GFI assesses mobility, physical fitness, assistance
needed with toileting and shopping, poor hearing and vi-
sion, medicine use, complaints about memory and de-
pression. It consists of 15 questions with a maximum
score of 15 points. The original cut-off value of ≥ 4 was
used to indicate frailty [15].
The G8 consists of eight questions about age, func-
tional status, cognitive status, nutrition and medication
use. The maximum score is 17 points. The original cut-
off value of ≤ 14 was used for indicating frailty [17]. The
specific G8 questions were not part of the interview; in-
stead, the answers were extracted from similar questions
asked at different parts of the interview.
The full CGA conducted in this study consists of five
domains: functional status, cognition, depression, nutri-
tional status and medication use. We used separate cut-
offs for each domain: a problem on at least two items of
the functional domain (ADL and IADL), a score of ≤ 23
on the MMSE or a score of ≥ 8 on the GDS-15. The ‘nu-
trition’ domain was considered positive if food intake de-
clined during the last week [28] or if there had been a
loss of at least one kilogram in weight over the last three
months [17]. For ‘medication use,’ we defined a cut-off
score of > 3 drugs. We used a proxy outcome for the full
CGA and considered frailty to be present if two or more
of the five domains scored positive.
Statistical analysis
For statistical analysis we used Statistical Package for the
Social Sciences (SPSS) version 19. We first described the
demographic and cancer-related clinical characteristics
of the participants (Table 2). To assess the diagnosticvalue of the different screening instruments, the sensitivity
(correctly classifying frail participants as positive), specifi-
city (correctly classifying non-frail participants as nega-
tive), the negative predictive value (NPV, proportion of
non-frail participants according to the full CGA in those
with a negative screening test result) and the positive pre-
dictive value (PPV, proportion of frail participants in those
with a positive screening test result) of the scores were
calculated together with their 95% confidence intervals
(CI). When there was no overlap in scores among the in-
struments (taking the CI into account), differences were
considered to be statistically significant. To estimate the
clinical usefulness of each screening instrument, we calcu-
lated the percentage of patients who each instrument clas-
sified as frail (and who thus had to be referred for a full
CGA) in addition to the PPV.
Furthermore, we varied the cut-off values of the four
screening instruments to investigate whether they re-
sulted in better outcomes. We first started with the
cut-off values as proposed in the original studies; there-
after, the cut-off value was increased and decreased by
one point.
Finally, diagnostic values were calculated separately for
patients diagnosed with breast cancer and patients diag-
nosed with gastrointestinal cancer, using the original
cut-off values.
For screening purposes a high sensitivity is generally
considered as the most important diagnostic characteris-
tic of an instrument. It is important for correctly diag-
nosing frailty so that an individual treatment plan can be
developed. However, a high specificity is also important
to avoid an unnecessary expensive and burdensome full
CGA. Therefore, we a priori defined a score of 85% or
higher for both sensitivity and specificity as adequate.
Table 2 Demographic and clinical characteristics of the
patients
Variable Patients aged ≥ 70
years with cancer
Patients aged ≥ 70
years without cancer
N % N %
All 108 290
- Male 38 35 105 36
Median age (range) 76 (70–88) 78 (70–97)
Living situation
- Not alone (partner
or children)
73 67 197 68
- Alone 31 29 88 30
- Nursing home 0 0 0 0
- Others 4 4 5 2
Cancer diagnosis
- Lung 7 6 0 0
- Breast 51 47 0 0
- Gastrointestinal 45 42 0 0
- Prostate 5 5 0 0
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As part of the KLIMOP study, this study was approved
by the Ethical Review Board of the Catholic University
(KU) Leuven and the University Hospitals Leuven
(S52097 - ML6279) (Belgium) and by the Medical Ethics
Committee of the Maastricht University Medical Centre
(NL31414.068.10) (The Netherlands). We applied good
clinical practice guidelines procedures (GCP) such as the
principles of the Declaration of Helsinki (October 2008
version), the Belgian law of 7 May 2004 concerning clin-
ical trials with humans and Dutch laws including the
Medical Research Involving Human Subjects Act and
the Personal Data Protection Act. Participants were only
included after giving written informed consent.
Results
Data were originally collected from 509 patients, but 111
were excluded because of incomplete data. Participants
excluded from the analysis were not different from those
included in the analysis regarding sex. They were slightly
older (mean 78,9 and 77,2, respectively, p = 0.033) and
more often had a diagnosis of cancer (54% and 18%, re-
spectively, p < 0.001).
Among these excluded patients, we were missing values
for the full CGA from 61 patients, for the aCGA from 58
patients, for the G8 from 19 patients, for the VES-13 from
12 patients and for the GFI from 59 patients.
Finally, data from 398 patients were available for ana-
lyses. The population characteristics are shown in Table 2.
The included population consisted of 108 patients with
cancer and 290 without cancer. About 65% were female
and about 35% were male. The male–female ratio wassimilar in patients with and without cancer. In both
groups most of the patients did not live alone (68%). In
the group with cancer, breast cancer (43%) and gastro-
intestinal malignancy (49%) were most represented. The
results of the four screening instruments are shown in
Table 3.
aCGA
Sensitivity was 85%, specificity was 63%, PPV was 68%
and NPV was 82%. The overall accuracy was 74%: 164
patients (41%) were correctly classified as frail and 129
patients (33%) were correctly classified as not frail. The
aCGA classified 60% of the patients as frail, compared to
48% with the full CGA. Sensitivity and NPV were lower
(79% and 75%, respectively) in the group with cancer
compared to the group without cancer (87% and 84%,
respectively). There were no significant differences in
specificity, PPV or classification as frail between the two
groups. Using a higher cut-off value (≥ 2) for the aCGA
led to fewer classifications of frailty (31%) and less sym-
metric scores on sensitivity (58%) and specificity (94%).
VES-13
Sensitivity was 78%, specificity was 76%, PPV was 75%
and NPV was 78%. The overall accuracy was 77%: 150
patients (38%) were correctly classified as frail and 156
patients (39%) were correctly classified as not frail. The
VES-13 classified 50% of the patients as frail, compared
to 48% with the full CGA. In the group with cancer, all
diagnostic values were significantly lower compared to
the group without cancer. The percentage of patients
classified as frail was lower in patients with cancer (48%)
compared to those without cancer (51%). Using a lower
cut-off value (≥ 2) for the VES-13 led to more classifica-
tions of frailty (55%) and less symmetric scores on sensi-
tivity (81%) and specificity (69%). Using a higher cut-off
value (≥ 4) led to fewer classifications of frailty (47%)
and somewhat less symmetric scores on sensitivity (74%)
and specificity (78%).
GFI
Sensitivity was 76%, specificity was 73%, PPV was 72%
and NPV was 76%. The overall accuracy was 74%: 146
patients (37%) were correctly classified as frail and 149
patients (37%) were correctly classified as not frail. The
GFI classified 51% of the patients as frail, compared to
48% with the full CGA. There were no differences in
diagnostic values between patients with and without
cancer. The percentage of patients with cancer who were
classified as frail (53%) was higher than in the group
without cancer (50%). Using a lower cut-off value (≥ 3)
for the GFI led to more classifications of frailty and less
symmetric scores on sensitivity (88%) and specificity
(59%). Using a higher cut-off value (≥ 5) led to fewer








aCGA CUT-OFF ≥ 1 CUT-OFF ≥ 2
Sensitivity 85 (81 – 88) 79 (71 – 87) 87 (83 – 91) 58 (53 – 63)
Specificity 63 (58 – 68) 59 (50 – 68) 64 (59 – 70) 94 (91 – 96)
PPV 68 (64 – 73) 64 (55 – 73) 70 (65 – 75) 90 (87 – 93)
NPV 82 (78 – 85) 75 (67 – 83) 84 (80 – 88) 70 (66 – 75)
Classified as frail 60 59 61 31
VES-13 CUT-OFF ≥ 3 CUT-OFF ≥ 2 CUT-OFF ≥ 4
Sensitivity 78 (74 – 82) 67 (58 – 76) 82 (77 – 86) 81 (77 – 85) 74 (70 – 78)
Specificity 76 (72 – 80) 70 (61 – 78) 79 (74 – 83) 69 (65 – 74) 78 (74 – 82)
PPV 75 (71 – 80) 67 (58 – 76) 78 (73 – 83) 71 (67 – 76) 76 (72 – 80)
NPV 78 (74 – 82) 70 (61 – 78) 82 (77 – 86) 79 (75 – 83) 76 (72 – 80)
Classified as frail 50 48 51 55 47
GFI CUT-OFF ≥ 4 CUT-OFF ≥ 3 CUT-OFF ≥ 5
Sensitivity 76 (71 – 86) 79 (61 – 87) 74 (69 – 79) 88 (84 – 91) 59 (54 – 63)
Specificity 73 (68 – 77) 71 (63 – 80) 73 (68 – 78) 49 (44 – 54) 83 (79 – 87)
PPV 72 (68 – 77) 72 (63 – 80) 72 (67 – 78) 62 (57 – 67) 76 (72 – 81)
NPV 76 (72–80) 78 (71 – 86) 75 (70 – 80) 81 (77 – 85) 68 (63 – 73)
Classified as frail 51 53 50 69 37
G8 CUT-OFF ≤ 14 CUT-OFF ≤ 13 CUT-OFF ≤ 15
Sensitivity 78 (74 – 82) 87 (80 – 93) 75 (70 – 80) 61 (56 – 65) 96 (94 – 98)
Specificity 68 (63 – 72) 64 (55 – 73) 69 (64 – 74) 86 (82 – 89) 39 (34 – 44)
PPV 70 (65 – 74) 69 (61 – 78) 70 (64 – 75) 80 (76 – 84) 60 (55 – 65)
NPV 77 (73 – 81) 84 (77 – 91) 75 (70 – 80) 70 (65 – 74) 91 (88 – 94)
Classified as frail 55 60 52 37 78
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sensitivity (59%) and specificity (83%).G8
Sensitivity was 78%, specificity was 68%, PPV was 70%
and NPV was 77%. The overall accuracy was 73%: 151
patients (38%) were correctly classified as frail and 139
patients (35%) were correctly classified as not frail. The
G8 classified 55% of the patients as frail, compared to
48% with the full CGA. Sensitivity and NPV were signifi-
cantly higher (87% and 84% respectively) in the group
with cancer compared to the group without cancer (75%
and 75% respectively). There were no significant differ-
ences in specificity and PPV between the two groups.
The percentage of patients classified as frail in the group
with cancer (60%) was higher than in the group without
cancer (52%). Using a lower cut-off value (≤ 13) led to
fewer classifications of frailty (37%) and less symmetric
scores on sensitivity (61%) and specificity (86%). Using a
higher cut-off value (≤ 15) led to more classifications offrailty (78%) and less symmetric scores on sensitivity
(96%) and specificity (39%).Stratified analysis
Sensitivity and specificity of the different screening tools
had largely overlapping confidence intervals for patients
with breast cancer, patients with gastro-intestinal cancer,
and the total group of cancer patients. Only for patients
with breast cancer the sensitivity of the VES-13 was
higher (75% vs. 67%), as was the specificity of the G8
(74% vs. 64%). For patients with gastro-intestinal cancer,
specificity of the G8 was lower (43% vs. 64%).Discussion
We evaluated the diagnostic value of four screening in-
struments (aCGA, VES-13, GFI and G8) using the CGA
as the reference standard to identify frailty in people
aged ≥ 70 years with and without cancer. No screening
instrument was acceptable according to our predefined
minimum of 85% for both sensitivity and specificity.
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groups with and without cancer, except for the GFI. Chan-
ging the cut-off points did not lead to more appropriate
results. This is disappointing because there is a big need
for good quality screening instruments in everyday care
for older people.
Comparison with previous research
Previous research outcomes are available but the results
vary widely [18]. Different results occurred in part be-
cause of differences in the definition of the full CGA in
previous studies, relating both to content and to cut-off
scores for domains. There were also differences in the
included study populations like age, presence of cancer
and type of cancer. Our study looked at older people
with and without cancer, which did not result in large
differences between these groups. The cancer patients
who were included in our study were recently diagnosed
with a primary breast, prostate, lung or gastrointestinal
cancer. The selected instruments used in this study, ex-
cluding the GFI [19], had previously mostly been evalu-
ated among older patients with different types of cancer
and were not validated in elderly patients without cancer.
Our study found sensitivity scores for the aCGA (85%)
and the GFI (76%) that were higher than those reported
in the study by Hamaker and colleagues [18]. This higher
sensitivity can be explained by using five instead of three
domains of the CGA as a reference standard or by the fact
that we also included people without cancer. Next in our
study, elderly patients with cancer scored lower (79%) on
sensitivity for the aCGA but higher (87%) on sensitivity
for the G8 compared to patients without cancer. This dif-
ference might be caused by the predominance of nutrition
in the G8 and the fact that malnutrition might be more
prevalent in cancer patients [29]. In addition, we only
included patients in the cancer group who were recently
diagnosed and not yet treated, and therefore who were
still in relatively good health. This might have influ-
enced the results.
The higher (76%) sensitivity score that we found for
the GFI as compared with the review of Hamaker and
colleagues [18] cannot be explained by differences in the
study population (with and without cancer) as our GFI
results were almost similar in patients with and without
cancer. The sensitivity and specificity values that we found
for the VES-13 and G8 all fell within the wide range that
Hamaker and colleagues [18] presented in their review. A
recent study by Biganzoli and colleagues [30] investigated
the cardiovascular health study instrument (CHS) and the
VES-13 in elderly cancer patients. They concluded that
the right screening tool is still missing because of the great
variability in specificity observed between subgroups that
differed in disease status (early or advanced) and type of
early cancer. This limits its applicability to the generalpopulation. Still, no good quality screening instrument
scoring ≥ 85% on both sensitivity and specificity has been
found. A review by Ruiz and colleagues [31] also con-
cluded that there is a need for a shorter reliable tool for
rapid and complete assessment.
Strengths and limitations
This study has several strengths. First, the study design
enabled us to provide external validation and comparison
of different screening instruments in the same population
and using the same reference standard. Second, we com-
pared elderly patients with and without cancer and were
therefore able to study the robustness of outcomes in
older persons from different samples. Third, we evaluated
different cut-off values for the screening instruments.
A study limitation is that we used a reference standard
based on the five most common CGA domains. However,
no consensus exists about which instruments or other
tests should be used for a full CGA [18]. Therefore, a
“gold” standard does not exist. A second limitation refers
to the operationalization of frailty using a full CGA. We
defined frailty as impairment on at least two domains of
the CGA. However, there is no consensus about the defin-
ition and operationalization of frailty yet. Using our defin-
ition, 48% of the participants were identified as frail. If we
would have used impairment on at least one domain as
cut-off for frailty, 73% of the participants would have been
classified as frail.
A third limitation is the predefined minimum of 85%
for both sensitivity and specificity. One could argue that
for screening instruments a high sensitivity might be pre-
ferred as it is crucial to minimize ‘false negatives’. How-
ever, a high specificity can also be considered important
because of costs for the organization and burden for the
patient. No literature was found about final thresholds so
we chose these cut-offs which may be arbitrary. A fourth
limitation is the lack of information about morbidity and
cancer stage. Unfortunately, this information is not avail-
able yet. A final limitation refers to the exclusion of pa-
tients with missing values. Excluded patients were slightly
older and more likely to have cancer. As our results are
presented for cancer and non-cancer patients separately,
this cannot have biased our results.
Implications of these study results
Sensitivity is important for selecting vulnerable patients
for a full CGA and ruling out the possibility of frailty.
Frailty is a state that might be fully or partly reversible
with the help of an individual treatment plan [8] includ-
ing interventions that can reverse or prevent it [9].
Diagnosing frailty and creating an individual treatment
plan might prevent complications and preserve a patient’s
autonomy. Hence, from the patient’s point of view, the
aCGA can be recommended for elderly patients without
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mended for elderly patients with cancer (sensitivity of
87%). Specificity is important for correctly selecting fit
individuals for whom no full CGA is indicated. This pre-
vents a patient from having to undergo an unnecessary
complete CGA, creating less of a burden for the patient
and reducing healthcare costs. However, none of the
screening instruments in this study showed a satisfying
specificity.
Taking these advantages for the patient and for health
care costs into account, a screening instrument with high
diagnostic values of sensitivity and specificity is preferred.
Therefore, we aspired to a score of at least 85% for both
sensitivity and specificity in order to use the instrument as
a screening tool for correctly selecting vulnerable people
for a full CGA. Nevertheless, we did not identify any high
scores on both sensitivity and specificity in any of the
available screening instruments included in this study.
The diagnostic value of the investigated instruments was
rather poor and one could wonder about their additional
value to clinical judgment.
Further research
The ultimate goal of screening for frailty is to predict out-
comes with respect to functioning and treatment. Much
more research will be necessary to develop a screening in-
strument that has appropriate diagnostic values, that is
suitable for distinguishing between frail and fit patients
and that can be used as a supporting tool for treatment
decisions. Second, since some differences in diagnostic
values exist between patients with and without cancer and
between patients with different types of cancer, further re-
search is needed to investigate whether specific diseases
need specific screening instruments to be more predictive.
Additionally, there is an urgent need for longitudinal stud-
ies on the diagnostic value of instruments for mid- and
long-term outcomes on factors like functional status,
institutionalization or mortality.
Conclusions
No screening instrument was acceptable according to
our predefined minimum of 85% for both sensitivity and
specificity. The diagnostic value of the investigated in-
struments is rather poor and one could wonder about
their additional value to clinical judgment.
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